Table 3.
Reported studies of ≥10 patients receiving chemotherapy for advanced penile cancer
| Author | Line of therapy | Regimen | Design | N | Clinical response N (%) | Median PFS | Median OS |
|---|---|---|---|---|---|---|---|
| Gagliano et al. [129] | First | Cisplatin | Phase II trial | 26 | 4 (15.4) | NR | 4.7 months |
| Haas et al. [132] | First | BMP | Phase II trial | 40 | 13 (32.5) | NR | 28 weeks |
| Dexeus et al. [131] | First | BMP | Retrospectivea | 14 | 10 (72) | NR | NR |
| Corral et al. [130] | First | BMP | Phase II trialb | 30 | 16 (55) | NR | 11.5 months |
| Di Lorenzo et al. [138] | First | CF | Retrospective | 25 | 8 (32) | 20 weeks | 8 months |
| Theodore et al. [140] | First | CI | Phase II trial | 28 | 8 (30.8) | NR | NR |
| Di Lorenzo et al. [142] | Second | Paclitaxelc | Phase II trial | 25 | 5 (20) | 11 weeks | 23 weeks |
aTwelve of the 14 patients had penile primary site.
bTrial enrolled patients with squamous cell carcinoma of the penis, scrotum, bladder, renal pelvis, ureter or urethra.
cPaclitaxel every 3 weeks.
BMP: bleomycin–methotrexate–cisplatin; CF: cisplatin–5-FU; CI: cisplatin–irinotecan; NR: not reported.